GTBP · GT Biopharma, Inc.

GT Biopharma operates in the competitive immuno-oncology space with its TriKE and Dual Targeting TriKE platforms, which engage patients' natural killer (NK) cells to target cancer antigens like B7-H3, HER2, CD33, and PDL1 across hematologic malignancies and solid tumors. The technology's key differentiator is its off-the-shelf nature—no patient-specific engineering required—and preclinical data suggesting lower risk of cytokine release syndrome compared to T-cell therapies due to NK cell selectivity and IL-15 driven proliferation. Initial development stemmed from collaboration with the University of Minnesota's Masonic Cancer Center under Dr. Jeffrey Miller, a key opinion leader in NK cell biology who serves as Consulting Senior Medical Director. This positions GTBP to potentially address broad markets if clinical programs advance, though no revenue or specific trial outcomes are detailed in the filing.

Financially, the company faces acute challenges. As a clinical-stage biotech with no disclosed revenue, it reports substantial going concern doubt, with cash insufficient to fund operations through one year from its 2025 10-K issuance date. Auditor Weinberg & Company highlighted this in their March 2026 report. Capital needs hinge on R&D progress, clinical trials, regulatory approvals, and patent enforcement, with historical cash burn tied to product development. Recent financing via the May 2025 Private Placement brought $5.95M gross (plus $9.4M from partial Greenshoe exercises), but ongoing 10-12% dividends on Series L Preferred and warrant liabilities add pressure. As of April 15, 2026, 35.6M common shares were outstanding, with dilutive overhang from warrants covering 58M shares (28M exercisable) at $0.62 average price and options for 598K shares at $4.23.

This S-1 registers 9.7M shares for resale by eight selling stockholders, primarily institutions like Bristol Investment Fund Ltd. (9.99% beneficial owner) and Five Narrow Lane (9.99%), stemming from Series L conversions (4.5M shares), vested warrants (4.5M), dividend shares (268K), and PDPC advisory pre-funded warrants (400K). Conversion price floored at $0.454 with full-ratchet anti-dilution; no company proceeds from resales, only potential warrant cash exercises. Ownership blockers cap holders at 4.99%/9.99%, but full exercise could massively dilute. Closing price was $0.27 on April 29, 2026, valuing the firm at minimal market cap.

Key risks center on Nasdaq delisting threat—the stock fell below $1 for 30 days by November 2025, with 180-day compliance window to May 19, 2026. Failure could trigger another period contingent on reverse split intent, impairing liquidity and capital access. Anti-takeover provisions (Section 203 DGCL, undesignated preferred, no cumulative voting) protect management but may deter suitors. Smaller reporting company status limits disclosure. Management includes CEO Michael Breen; no detailed backgrounds provided. Investors face high dilution, penny stock restrictions, and execution risks in advancing TriKEs to commercialization without near-term cash flow.